River BioMedics, a drug discovery company using advanced 3D human cardiac models, announced the seed funding of 1.8 million Euro to progress its pipeline of cardiovascular disease targets and compounds. River BioMedics addresses the high unmet medical need of cardiac diseases with a focus on heart failure. The financing round was co-led by FIRST fund, managed by BioGeneration Ventures (BGV), KIKK Capital and Oost NL.
River BioMedics was founded in 2020 by Marcelo Ribeiro, Lisanne Blauw and Robert Passier, as a spin-out from the University of Twente’s department of Applied Stem Cell Technologies. The team has built a suite of 3D cardiac models including, 3D cardiac strips, heart-on-a-chip and the highly innovative mini heart, to support their drug discovery programs and enable partnerships. With the current financing round, River BioMedics will start 2 drug discovery programs on cardiac specific targets. The founders have a complementary background in the cardiovascular field. Marcelo is specialized in hiPSC-derived cardiomyocyte maturation and disease modelling, Lisanne has a background in cardiovascular genetics and Robert is professor and chair of the department of Applied Stem Cell Technologies at the University of Twente. For more information: www.riverbiomedics.com
For the full press release click here.
Source: https://riverbiomedics.com
